MetaCap

Aclaris Therapeutics (ACRS) vs Alumis (ALMS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aclaris Therapeutics (ACRS) has outperformed Alumis (ALMS) over the past year, gaining 37.1% versus a loss of 45.8%. Aclaris Therapeutics is the larger company by market cap ($545.6 million vs $514.1 million), about 1.1 times the size. Aclaris Therapeutics converts more of its revenue into profit, with a net margin of -829.6% versus -1011.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACRS+37.05%ALMS-45.75%
+333%+135%-64%
Nov 21, 20251 yearNov 20, 2026
ACRS+212.73%ALMS-70.23%
+511%+202%-107%
Jun 24, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACRS versus ALMS key metrics
MetricACRSALMS
Share price$3.44$3.96
Market cap$545.63M$514.09M
1-day change-1.71%-8.55%
YTD return+14.29%-59.43%
1-year return+37.05%-45.75%
5-year return-72.74%—
EPS (TTM)$-0.59$-3.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.83M$24.05M
Revenue growth (YoY)-58.19%—
Net income (latest FY)$-64.92M$-243.32M
Gross margin73.28%—
Operating margin-975.91%-1886.92%
Net margin-829.58%-1011.75%
52-week high$6.60$31.35
52-week low$2.46$3.94
Distance from 52-week high-47.88%-87.37%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+205.23%+540.91%
Average volume3.07M2.87M
Shares outstanding158.61M129.82M
Employees69251
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ACRS has outperformed ALMS by 82.8 percentage points over the past year.
  • Aclaris Therapeutics is more profitable, keeping -829.6 cents of every revenue dollar as net income versus -1011.7 cents for Alumis.

About Aclaris Therapeutics

ACRS stock →

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Alumis

ALMS stock →

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 251 employees

ACRS vs ALMS FAQ

Which is bigger, Aclaris Therapeutics or Alumis?

Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $545.63M compared with $514.09M for Alumis (ALMS).

Which stock has performed better over the past year, ACRS or ALMS?

ACRS returned +37.05% over the past 12 months, compared with -45.75% for ALMS (price return, excluding dividends). Past performance does not predict future results.

Are Aclaris Therapeutics and Alumis in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons